These systematic approaches are becoming increasingly sophisticated and moving past traditional chemotherapy to become more genetically focused, addressing the key drivers of cancer.

The targeting of oncogenic processes with the identification of enriched populations has been successfully demonstrated in lung cancer, melanoma, and acute myeloid leukemia with multiple approvals of small molecules, such as kinase and checkpoint inhibitors. Adastra is leveraging the mechanism of our lead drug candidate to overcome challenges commonly faced in oncology.